Ifeanyichukwu Ifechidere: The Molecular Orchestra of Primary Hemostasis
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals, shared a post on LinkedIn:
“What if I told you platelets don’t ‘stop bleeding’… at least not in the way most of us were taught?
We often learn primary hemostasis as a neat little sequence:
Vessel injury
- Platelet adhesion
- Platelet activation
- Platelet aggregation
- Plug formation
Simple, right?
But then the questions start getting uncomfortable…
Why does a platelet need to change shape?
Why does adhesion require more than just ‘platelets sticking to the damaged vessel’?
Why is von Willebrand factor so important in this process?
And perhaps the more interesting question:
If platelets are so good at forming a plug, why doesn’t every small vascular injury result in uncontrolled thrombosis?
Something has to regulate this process.
And the platelet is doing far more than simply ‘plugging the hole.’
There’s a fascinating conversation happening between the injured vessel, endothelial cells, von Willebrand factor, platelet receptors, agonists, granules and coagulation factors.
Miss one piece, and suddenly primary hemostasis doesn’t look quite as simple as the textbook diagram suggests.
So here’s my question:
Do we really understand what the platelet is doing during primary hemostasis—or have we just memorized the steps?
I’m going to be unpacking this from the ground up in our upcoming Platelet Bootcamp.
Not just what happens.
But why it happens, how it happens, and what changes when something goes wrong.
If platelets have always felt like a collection of pathways you had to memorize, follow me.
We’re going to make the platelet make sense.
The rabbit hole starts with primary hemostasis.”

Other posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines